

## (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 19 February 2004 (19.02.2004)

**PCT** 

## (10) International Publication Number WO 2004/015070 A3

(51) International Patent Classification<sup>7</sup>: C12P 19/34

G01N 33/53,

(21) International Application Number:

PCT/US2003/024548

(22) International Filing Date: 6 August 2003 (06.08.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/402,521

8 August 2002 (08.08.2002) US

- (71) Applicants (for all designated States except US): BAY-LOR COLLEGE OF MEDICINE [US/US]; One Baylor Plaza, Houston, TX.77030 (US). OPEXA PHARMA-CEUTICALS INC. [US/US]; 835 Green Parkway, Suite 150, Houston, TX 77067 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): ZHANG, Jingwu, Z. [US/US]; 2219 Parkview Lane, Missouri City, TX 77459 (US).
- (74) Agents: CLOUGH, David, W. et al.; Katten Muchin Zavis Rosenman, 525 W. Monroe Street, Suite 1600, Chicago, IL 60661-3693 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
  11 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(57) Abstract: The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention is further directed to the diagnosis of T cell associated diseases.





OUR TIPTO

04FEB 2005

10/524300

## INTERNATIONAL SEARCH REPORT

Form PCT/ISA/210 (second sheet) (July 1998)

International application No.

PCT/US03/24548

A. CLASSIFICATION OF SUBJECT MATTER						
IPC(7) : G01N 33/53; C12P 19/34 US CL : 424/7.21, 93.7; 435/91.2						
US CL: 424/7.21, 93.7; 435/91.2 According to International Patent Classification (IPC) or to both national classification and IPC						
B. FIELDS SEARCHED						
Minimum documentation searched (classification system followed by classification symbols)						
U.S.: 424/7.21, 93.7; 435/91.2						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet						
C. DOC	5.1 11. 37.					
Category *	Citation of document, with indication, where ap	propriate,	of the relevant passages	Relevant to claim No.		
Y	HERMANS et al. Cytokine Profile of Myelin Basic Sclerosis and Healthy Individuals. Annals of Neurol 27, see entire article.	Protein-Re ogy. 1997	active T Cells in Multiple, Vol. 42, No. 1, pages 18-	1-30		
Y	ZHANG et al. Th2 immune regulation induced by T cell vaccination i patients with mutiple sclerosis. European Journal of Immunology. March 2000, Vol. 30, pages 908-913, see entire article.			1-30		
Y	US 6,303,314 B1 (ZHANG, J. Z.) 16 October 2001 (16.10.2001), see entire document.			1-30		
ļ						
ļ			• •			
1			•			
			,			
İ						
			•			
Further documents are listed in the continuation of Box C. See patent family annex.						
* !	Special caregories of cited documents:	"T"	later document published after the inte date and not in conflict with the appli	ernational filing date or priority eation but cited to understand the		
"A" documen	at defining the general state of the art which is not considered to be		principle or theory underlying the inv	ention		
"E" earlier a	ular relevance  pplication or patent published on or after the international filing date	"X"	document of particular relevance; the considered novel or cannot be conside when the document is taken alone	claimed invention cannot be red to involve an inventive step		
"L" documer establish specified	nt which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as i)	"Y"	document of particular relevance; the considered to involve an inventive ste combined with one or more other suc	p when the document is		
"O" documen	nt referring to an oral disclosure, use, exhibition or other means		being obvious to a person skilled in the	e art		
priority	nt published prior to the international filing date but later than the date claimed	"&"	document member of the same patent			
Date of the actual completion of the international search		Authorized offices Surface Sur				
09 April 2004 (09.04.2004)		Nucharia	ed officer C	UEF /III4		
Name and mailing address of the ISA/US		12 10	Thia Knull	ence y_		
Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Marianne DiBrino, Phys. 1000 1000 1000				
P.O. Box 1450 Alexandria, Virginia 22313-1450		Telephor	ne No. 571-272-1600			
Facsimile N	o. (703)305-3230					





PCT/US03/2454

Continuation of B. FIELDS SEARCHED Item 3:	
WEST 2.1, STN(EMBASE, BIOSIS, MEDLINE, CAPLUS, SCISEARCH, P	'n
wash as inventor's page cd60 cd4 cd25 blade il-2 il-5 il-10 il-13.	if

PROMT, BIOBUSINESS)
3, ifn-g, tnfa, cd36, autoantigens, autoimmunity, treat/ment, search terms: inventor's name, cd69, cd4, cd25, hla-dr, il-2, il-5, il-10, myelin basic protein, mbp, activated T cells, 83-99, 151-170.

Form PCT/ISA/210 (second sheet) (July 1998)